Current status of leukotriene A₄ hydrolase inhibitors

Bibliography

• Kim N, Luster AD. Regulation of immune cells by eicosanoid receptors. Sci World J 2007;7:1307-28
   Google Scholar
• Rubin P, Mollison KW. Pharmacotherapy of diseases mediated by 5-lipoxygenase pathway eicosanoids. Prostaglandins Other Lipid Mediat 2007;83(3):188-97
   PubMed Web of Science ®Google Scholar
• Peters-Golden M, Henderson WR Jr. Leukotrienes. N Engl J Med 2007;357(18)1841-54
   PubMed Web of Science ®Google Scholar
• Borgeat P, Hamberg M, Samuelsson B. Transformation of arachidonic acid and homo-gamma-linolenic acid by rabbit polymorphonuclear leukocytes. Monohydroxy acids from novel lipoxygenases. J Biol Chem 1976;251(24)7816-20
   PubMed Web of Science ®Google Scholar
• Brocklehurst WE. Slow reacting substance and related compounds. Prog Allergy 1962;6:539-58
   PubMedGoogle Scholar
• Borgeat P, Sirois P. Leukotrienes: a major step in the understanding of immediate hypersensitivity reactions. J Med Chem 1981;24(2):121-6
   PubMed Web of Science ®Google Scholar
• Haeggstrom JZ. Leukotriene A4 hydrolase/aminopeptidase, the gatekeeper of chemotactic leukotriene B4 biosynthesis. J Biol Chem 2004;279(49):50639-42
   PubMed Web of Science ®Google Scholar
• Haeggstrom JZ, Kull F, Rudberg PC, et al. Leukotriene A4 hydrolase. Prostaglandins Other Lipid Mediat 2002;68-69:495-510
   Google Scholar
• Del Prete A, Shao W-H, Mitola S, et al. Regulation of dendritic cell migration and adaptive immune response by leukotriene B4 receptors: a role for LTB4 in up-regulation of CCR7 expression and function. Blood 2007;109(2):626-31
   PubMedGoogle Scholar
• Goetzl EJ, Goldman DW, Naccache PH, et al. Mediation of leukocyte components of inflammatory reactions by lipoxygenase products of arachidonic acid. Adv Prostaglandin Thromboxane Leukot Res 1982;9:273-82
   PubMedGoogle Scholar
• Goodarzi K, Goodarzi M, Tager AM, et al. Leukotriene B4 and BLT1 control cytotoxic effector T cell recruitment to inflamed tissues. Nat Immunol 2003;4(10):965-73
   PubMed Web of Science ®Google Scholar
• Heller EA, Liu E, Tager AM, et al. Inhibition of atherogenesis in BLT1-deficient mice reveals a role for LTB4 and BLT1 in smooth muscle cell recruitment. Circulation 2005;112(4):578-86
   PubMed Web of Science ®Google Scholar
• Iizuka Y, Yokomizo T, Terawaki K, et al. Characterization of a mouse second leukotriene B4 receptor, mBLT2: BLT2-dependent ERK activation and cell migration of primary mouse keratinocytes. J Biol Chem 2005;280(26):24816-23
   PubMedGoogle Scholar
• Lundeen KA, Sun B, Karlsson L, Fourie AM. Leukotriene B4 receptors BLT1 and BLT2: expression and function in human and murine mast cells. J Immunol 2006;177(5):3439-47
   PubMed Web of Science ®Google Scholar
• Munoz NM, Douglas I, Mayer D, et al. Eosinophil chemotaxis inhibited by 5-lipoxygenase blockade and leukotriene receptor antagonism. Am J Respir Crit Care Med 1997;155(4):1398-403
   PubMed Web of Science ®Google Scholar
• Ott VL, Cambier JC, Kappler J, et al. Mast cell-dependent migration of effector CD8+ T cells through production of leukotriene B4. Nat Immunol 2003;4(10):974-81
   PubMed Web of Science ®Google Scholar
• Tager AM, Bromley SK, Medoff BD, et al. Leukotriene B4 receptor BLT1 mediates early effector T cell recruitment. Nat Immunol 2003;4(10):982-90
   PubMed Web of Science ®Google Scholar
• Rask-Madsen J. Soluble mediators and the interaction of drugs in IBD. Drugs Today Barc 1998;34(1):45-63
   PubMedGoogle Scholar
• Sharon P, Stenson WF. Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. Gastroenterology 1984;86(3):453-60
   PubMed Web of Science ®Google Scholar
• Griffiths RJ, Pettipher ER, Koch K, et al. Leukotriene B4 plays a critical role in the progression of collagen-induced arthritis. Proc Natl Acad Sci USA 1995;92(2):517-21
   PubMed Web of Science ®Google Scholar
• Shao WH, Del Prete A, Bock CB, Haribabu B. Targeted disruption of leukotriene B4 receptors BLT1 and BLT2: a critical role for BLT1 in collagen-induced arthritis in mice. J Immunol 2006;176(10):6254-61
   PubMed Web of Science ®Google Scholar
• Tsuji F, Oki K, Fujisawa K, et al. Involvement of leukotriene B4 in arthritis models. Life Sci 1999;64(3):PL51-6
   PubMed Web of Science ®Google Scholar
• Barnes PJ. New treatments for COPD. Nat Rev Drug Discov 2002;1(6):437-46
   PubMed Web of Science ®Google Scholar
• Gompertz S, Stockley RA. A randomized, placebo-controlled trial of a leukotriene synthesis inhibitor in patients with COPD. Chest 2002;122(1):289-94
   PubMed Web of Science ®Google Scholar
• Lemiere C, Pelissier S, Tremblay C, et al. Leukotrienes and isocyanate-induced asthma: a pilot study. Clin Exp Allergy 2004;34(11):1684-9
   PubMed Web of Science ®Google Scholar
• Luster AD, Tager AM. T-cell trafficking in asthma: lipid mediators grease the way. Nat Rev Immunol 2004;4(9):711-24
   PubMed Web of Science ®Google Scholar
• Terawaki K, Yokomizo T, Nagase T, et al. Absence of leukotriene B4 receptor 1 confers resistance to airway hyperresponsiveness and Th2-type immune responses. J Immunol 2005;175(7):4217-25
   PubMed Web of Science ®Google Scholar
• Montuschi P, Sala A, Dahlen SE, Folco G. Pharmacological modulation of the leukotriene pathway in allergic airway disease. Drug Discov Today 2007;12(9-10):404-12
   PubMed Web of Science ®Google Scholar
• Chen X, Wang S, Wu N, Yang CS. Leukotriene A4 hydrolase as a target for cancer prevention and therapy. Curr Cancer Drug Targets 2004;4(3):267-83
   PubMed Web of Science ®Google Scholar
• Back M, Bu DX, Branstrom R, et al. Leukotriene B4 signaling through NF-kappaB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. Proc Natl Acad Sci USA 2005;102(48):17501-6
   PubMed Web of Science ®Google Scholar
• Back M, Hansson GK. Leukotriene receptors in atherosclerosis. Ann Med 2006;38(7):493-502
   PubMed Web of Science ®Google Scholar
• Friedrich EB, Tager AM, Liu E, et al. Mechanisms of leukotriene B4–triggered monocyte adhesion. Arterioscler Thromb Vasc Biol 2003;23(10):1761-7
   PubMed Web of Science ®Google Scholar
• Funk CD. Leukotriene modifiers as potential therapeutics for cardiovascular disease. Nat Rev Drug Discov 2005;4(8):664-72
   PubMed Web of Science ®Google Scholar
• Helgadottir A, Gretarsdottir S, St Clair D, et al. Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a Scottish population. Am J Hum Genet 2005;76(3):505-9
   PubMed Web of Science ®Google Scholar
• Helgadottir A, Manolescu A, Helgason A, et al. A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat Genet 2006;38(1):68-74
   PubMed Web of Science ®Google Scholar
• Helgadottir A, Manolescu A, Thorleifsson G, et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 2004;36(3):233-9
   PubMed Web of Science ®Google Scholar
• Jala VR, Haribabu B. Leukotrienes and atherosclerosis: new roles for old mediators. Trends Immunol 2004;25(6):315-22
   PubMed Web of Science ®Google Scholar
• Qiu H, Gabrielsen A, Agardh HE, et al. Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability. Proc Natl Acad Sci USA 2006;103(21):8161-6
   PubMed Web of Science ®Google Scholar
• Subbarao K, Jala VR, Mathis S, et al. Role of leukotriene B4 receptors in the development of atherosclerosis: potential mechanisms. Arterioscler Thromb Vasc Biol 2004;24(2):369-75
   PubMed Web of Science ®Google Scholar
• Whatling C, McPheat W, Herslof M. The potential link between atherosclerosis and the 5-lipoxygenase pathway: investigational agents with new implications for the cardiovascular field. Expert Opin Investig Drugs 2007;16(12):1879-93
   PubMed Web of Science ®Google Scholar
• Byrum RS, Goulet JL, Snouwaert JN, et al. Determination of the contribution of cysteinyl leukotrienes and leukotriene B4 in acute inflammatory responses using 5-lipoxygenase- and leukotriene A4 hydrolase-deficient mice. J Immunol 1999;163(12):6810-9
   PubMed Web of Science ®Google Scholar
• Chen M, Lam BK, Kanaoka Y, et al. Neutrophil-derived leukotriene B4 is required for inflammatory arthritis. J Exp Med 2006;203(4):837-42
   PubMed Web of Science ®Google Scholar
• Brooks CD, Summers JB. Modulators of leukotriene biosynthesis and receptor activation. J Med Chem 1996;39(14):2629-54
   PubMed Web of Science ®Google Scholar
• Evans JF, Ferguson AD, Mosley RT, Hutchinson JH. What's all the FLAP about: 5-lipoxygenase-activating protein inhibitors for inflammatory diseases. Trends Pharmacol Sci 2008;29(2):72-8
   PubMed Web of Science ®Google Scholar
• Peters-Golden M, Brock TG. 5-lipoxygenase and FLAP. Prostaglandins Leukot Essent Fatty Acids 2003;69(2-3):99-109
   PubMed Web of Science ®Google Scholar
• Vickers PJ. 5-Lipoxygenase-activating protein (FLAP). J Lipid Mediat Cell Signal 1995;12(2-3):185-94
   PubMedGoogle Scholar
• Hicks A, Monkarsh SP, Hoffman AF, Goodnow R Jr. Leukotriene B4 receptor antagonists as therapeutics for inflammatory disease: preclinical and clinical developments. Expert Opin Investig Drugs 2007;16(12):1909-20
   PubMed Web of Science ®Google Scholar
• Yokomizo T, Kato K, Terawaki K, et al. A second leukotriene B4; receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. J Exp Med 2000;192(3):421-32
   PubMed Web of Science ®Google Scholar
• Kamohara M, Takasaki J, Matsumoto M, et al. Molecular cloning and characterization of another leukotriene B4 receptor. J Biol Chem 2000;275(35):27000-4
   PubMedGoogle Scholar
• Tryselius Y, Nilsson NE, Kotarsky K, et al. Cloning and characterization of cDNA encoding a novel human leukotriene B4; receptor. Biochem Biophys Res Commun 2000;274(2):377-82
   PubMedGoogle Scholar
• Wang S, Gustafson E, Pang L, et al. A novel hepatointestinal leukotriene B4 receptor. Cloning and functional characterization. J Biol Chem 2000;275(52):40686-94
   PubMed Web of Science ®Google Scholar
• Yokomizo T, Izumi T, Chang K, et al. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature 1997;387(6633):620-4
   PubMed Web of Science ®Google Scholar
• Serhan CN, Hamberg M, Samuelsson B. Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes. Proc Natl Acad Sci USA 1984;81(17):5335-9
   PubMed Web of Science ®Google Scholar
• Serhan CN. Resolution Phase of Inflammation: Novel Endogenous Anti-Inflammatory and Proresolving Lipid Mediators and Pathways. Annu Rev Immunol 2007;25(1):101-37
   PubMed Web of Science ®Google Scholar
• Rao NL, Dunford PJ, Xue X, et al. Anti-inflammatory activity of a potent, selective leukotriene A4 hydrolase inhibitor in comparison with the 5-lipoxygenase inhibitor zileuton. J Pharmacol Exp Ther 2007;321(3):1154-60
   PubMed Web of Science ®Google Scholar
• Penning TD, Chandrakumar NS, Chen BB, et al. Structure-activity relationship studies on 1-[2-(4-Phenylphenoxy)ethyl]pyrrolidine (SC-22716), a potent inhibitor of leukotriene A4; (LTA4;) hydrolase. J Med Chem 2000;43(4):721-35
   PubMed Web of Science ®Google Scholar
• Penning TD, Russell MA, Chen BB, et al. Synthesis of potent leukotriene A4; hydrolase inhibitors. Identification of 3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid. J Med Chem 2002;45(16):3482-90
   PubMed Web of Science ®Google Scholar
• Thunnissen MM, Nordlund P, Haeggstrom JZ. Crystal structure of human leukotriene A4; hydrolase, a bifunctional enzyme in inflammation. Nat Struct Biol 2001;8(2):131-5
   PubMedGoogle Scholar
• Thunnissen MM, Andersson B, Samuelsson B, et al. Crystal structures of leukotriene A4 hydrolase in complex with captopril and two competitive tight-binding inhibitors. Faseb J 2002;16(12):1648-50
   PubMed Web of Science ®Google Scholar
• Penning TD. Inhibitors of leukotriene A4 (LTA4) hydrolase as potential anti-inflammatory agents. Curr Pharm Des 2001;7(3):163-79
   PubMed Web of Science ®Google Scholar
• Friesen RW, Riendeau D. Leukotriene Biosynthesis Inhibitors. Annual Reports in Medicinal Chemistry: Academic Press. 2005:199-214
   Google Scholar
• Orning L, Krivi G, Fitzpatrick FA. Leukotriene A4 hydrolase. Inhibition by bestatin and intrinsic aminopeptidase activity establish its functional resemblance to metallohydrolase enzymes. J Biol Chem 1991;266(3):1375-8
   PubMed Web of Science ®Google Scholar
• Penning TD, Askonas LJ, Djuric SW, et al. Kelatorphan and related analogs: potent and selective inhibitors of leukotriene A4 hydrolase. Bioorg Med Chem Lett 1995;5(21):2517-22
   Web of Science ®Google Scholar
• Tsuji F, Miyake Y, Enomoto H, et al. Effects of SA6541, a leukotriene A4 hydrolase inhibitor, and indomethacin on carrageenan-induced murine dermatitis. Eur J Pharmcol 1998;346(1):81-5
   PubMed Web of Science ®Google Scholar
• British Biotech Pharmaceuticals Limited: WO199940910; 1999
   Google Scholar
• Novel leukotriene A4 hydrolase inhibitors. Expert Opin Ther Patents 1999;9(1):91-5
   Web of Science ®Google Scholar
• G.D. Searle & Co.: WO199611192; 1996
   Google Scholar
• G.D. Searle & Co.: WO199610999; 1996
   Google Scholar
• G.D. Searle & Co.: US5,585,492; 1996
   Google Scholar
• G.D. Searle & Co.: US5,719,306; 1998
   Google Scholar
• G.D. Searle & Co.: US5,723492; 1998
   Google Scholar
• G.D. Searle & Co.: US6,506,876; 2003
   Google Scholar
• Penning TD, Chandrakumar NS, Desai BN, et al. Pyrrolidine and piperidine analogues of SC-57461A as potent, orally active inhibitors of leukotriene A4; hydrolase. Bioorg Med Chem Lett 2002;12(23):3383-6
   PubMed Web of Science ®Google Scholar
• G.D. Searle & Co.: WO199644625; 1996
   Google Scholar
• G.D. Searle & Co.: WO199729774; 1997
   Google Scholar
• G.D. Searle & Co.: US5,990,148; 1999
   Google Scholar
• G.D. Searle & Co.: US5,700,816; 1997
   Google Scholar
• G.D. Searle & Co.: US6407140B1; 2002
   Google Scholar
• G.D. Searle & Co.: WO199840354; 1998
   Google Scholar
• G.D. Searle & Co.: US6,162,823; 2000
   Google Scholar
• G.D. Searle & Co.: WO199840364; 1998
   Google Scholar
• G.D. Searle & Co.: US5,925,654; 1999
   Google Scholar
• G.D. Searle & Co.: US6,265,433B1; 2001
   Google Scholar
• G.D. Searle & Co.: WO199840370; 1998
   Google Scholar
• G.D. Searle & Co.: US 6,110,944; 2000
   Google Scholar
• Janssen Pharmaceutica N.V.: WO2005012297; 2005
   Google Scholar
• Janssen Pharmaceutica N.V.: WO2005012296; 2005
   Google Scholar
• Janssen Pharmaceutica N.V.: WO2006105304; 2006
   Google Scholar
• These applications are assigned to either deCODE Chemistry, Inc. or deCODE genetics ehf
   Google Scholar
• deCODE Chemistry, Inc.: US20070066820; 2007
   Google Scholar
• Sandanayaka V, Mamat B, Yu P, et al. DG-051: A novel leukotriene A4 hydrolase inhibitor for the treatment of myocardial infarction and stroke. The 233rd ACS National Meeting, 2007 March 25-29; Chicago: IL, USA
   Google Scholar
• deCODE Announces Positive Topline Results for Phase I Study of DG051 for the Prevention of Heart Attack. Available from: http://www.decode.com/News/2007_05_01.php
   Google Scholar
• deCODE Launches Phase II Clinical Testing of DG051 for the Prevention of Heart Attack. Available from: http://www.decode.com/News/2007_10_09.php
   Google Scholar
• Sandanayaka V, Mamat B, Bedell L, et al. Design, synthesis, and SAR of novel leukotriene A4 hydrolase inhibitors containing chiral piperidine and piperazine scaffolds. 232nd ACS National Meeting, 2006 September 10-14; San Francisco: CA, USA
   Google Scholar
• Zhao L, Mamat B, Mishra R, et al. Discovery of indazole derivatives as potent leukotriene A4 hydrolase inhibitors. 232nd ACS National Meeting, 2006 September 10-14; San Francisco: CA, USA
   Google Scholar
• deCODE Chemistry, Inc.: WO2007073407; 2007
   Google Scholar
• deCODE Chemistry, Inc.: US20070142432; 2007
   Google Scholar
• deCODE Chemistry, Inc.: WO2007073405; 2007
   Google Scholar
• deCODE Chemistry, Inc.: US20070142434; 2007
   Google Scholar
• deCODE genetics, ehf.: US20080033013; 2008
   Google Scholar
• deCODE Chemistry, Inc.: US20070149544; 2007
   Google Scholar
• deCODE genetics, ehf.: US20080033024; 2008
   Google Scholar
• deCODE genetics, ehf.: US2008019284; 2008
   Google Scholar
• Schering AG: US20070155726; 2007
   Google Scholar
• Schering AG: WO2007079003; 2007
   Google Scholar
• Schering AG: US20070155727; 2007
   Google Scholar
• deCODE genetics Announces First Quarter 2008 Financial Results. Available from: http://www.decode.com/News/2008_05_01.php
   Google Scholar